Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human Brain: Clinical Implications
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
CONTEXT: Modafinil, a wake-promoting drug used to treat narcolepsy, is increasingly being used as a cognitive enhancer. Although initially launched as distinct from stimulants that increase extracellular dopamine by targeting dopamine transporters, recent preclinical studies suggest otherwise. OBJECTIVE: To measure the acute effects of modafinil at doses used therapeutically (200 mg and 400 mg given orally) on extracellular dopamine and on dopamine transporters in the male human brain. DESIGN, SETTING, AND PARTICIPANTS: Positron emission tomography with [(11)C]raclopride (D(2)/D(3) radioligand sensitive to changes in endogenous dopamine) and [(11)C]cocaine (dopamine transporter radioligand) was used to measure the effects of modafinil on extracellular dopamine and on dopamine transporters in 10 healthy male participants. The study took place over an 8-month period (2007-2008) at Brookhaven National Laboratory. MAIN OUTCOME MEASURES: Primary outcomes were changes in dopamine D(2)/D(3) receptor and dopamine transporter availability (measured by changes in binding potential) after modafinil when compared with after placebo. RESULTS: Modafinil decreased mean (SD) [(11)C]raclopride binding potential in caudate (6.1% [6.5%]; 95% confidence interval [CI], 1.5% to 10.8%; P = .02), putamen (6.7% [4.9%]; 95% CI, 3.2% to 10.3%; P = .002), and nucleus accumbens (19.4% [20%]; 95% CI, 5% to 35%; P = .02), reflecting increases in extracellular dopamine. Modafinil also decreased [(11)C]cocaine binding potential in caudate (53.8% [13.8%]; 95% CI, 43.9% to 63.6%; P < .001), putamen (47.2% [11.4%]; 95% CI, 39.1% to 55.4%; P < .001), and nucleus accumbens (39.3% [10%]; 95% CI, 30% to 49%; P = .001), reflecting occupancy of dopamine transporters. CONCLUSIONS: In this pilot study, modafinil blocked dopamine transporters and increased dopamine in the human brain (including the nucleus accumbens). Because drugs that increase dopamine in the nucleus accumbens have the potential for abuse, and considering the increasing use of modafinil, these results highlight the need for heightened awareness for potential abuse of and dependence on modafinil in vulnerable populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arky, R. A. (1994) · Cited by 2,632
Logan, J., Fowler, J. S., Volkow, N. D., Wolf, A. P., Dewey, S. L., Schlyer, D. J., MacGregor, R. R., Hitzemann, R., Bendriem, B., Gatley, S. J., et al. (1990) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1990.127 · Cited by 1,479
Self-citationCrone, C. (1963) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1963.tb02652.x · Cited by 1,153
Volkow, N. D., Wang, G.-J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y.-S., Hitzemann, R., & Pappas, N. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1325 · Cited by 885
Self-citationDopaminergic Role in Stimulant-Induced Wakefulness
Wisor, J. P., Nishino, S., Sora, I., Uhl, G. H., Mignot, E., & Edgar, D. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-05-01787.2001 · Cited by 769
Modafinil: a review of neurochemical actions and effects on cognition
Minzenberg, M. J., & Carter, C. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301534 · Cited by 713 · cited 1×
“Modafinil may enhance cognition and is used off-label for the treatment of cognitive dysfunction in some psychiatric disorders (ie, schizophrenia, attention-deficit/ hyperactivity disorder [ADHD]).(1) Moreover, modafinil is increasingly being diverted for nonmedical use by healthy individuals with the expectation that…”
BackgroundHypothalamic Arousal Regions Are Activated during Modafinil-Induced Wakefulness
Scammell, T. E., Estabrooke, I. V., McCarthy, M. T., Chemelli, R. M., Yanagisawa, M., Miller, M. S., & Saper, C. B. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-22-08620.2000 · Cited by 485
Volkow, N. D., Wang, G., Fowler, J. S., Logan, J., Jayne, M., Franceschi, D., Wong, C., Gatley, S. J., Gifford, A. N., Ding, Y., et al. (2002) · Synapse · doi:10.1002/syn.10075 · Cited by 452
Self-citationThe Physicians' Desk Reference: Problems and Possible Improvements
Cohen, J. S. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440120021003 · Cited by 428
A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300600 · Cited by 391
Cited by
The dopamine theory of addiction: 40 years of highs and lows
Nutt, D. J., Lingford-Hughes, A., Erritzoe, D., & Stokes, P. R. A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3939 · Cited by 649
Scofield, M. D., Heinsbroek, J. A., Gipson, C. D., Kupchik, Y. M., Spencer, S., Smith, A. C. W., Roberts-Wolfe, D., & Kalivas, P. W. (2016) · Pharmacological Reviews · doi:10.1124/pr.116.012484 · Cited by 598
“best-characterized cellular target is the dopamine transporter (Volkow et al., 2009), but it modulates the”
BackgroundModafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review
Repantis, D., Schlattmann, P., Laisney, O., & Heuser, I. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.04.002 · Cited by 576
The comorbidity of insomnia, chronic pain, and depression: Dopamine as a putative mechanism
Finan, P. H., & Smith, M. T. (2013) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2012.03.003 · Cited by 363
Brain default-mode network dysfunction in addiction
Zhang, R., & Volkow, N. D. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.06.036 · Cited by 363
Self-citationPitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial
Dauvilliers, Y., Bassetti, C., Lammers, G. J., Arnulf, I., Mayer, G., Rodenbeck, A., Lehert, P., Ding, C.-L., Lecomte, J.-M., & Schwartz, J.-C. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70225-4 · Cited by 362
New medications for drug addiction hiding in glutamatergic neuroplasticity
Kalivas, P. W., & Volkow, N. D. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.46 · Cited by 349
Self-citationNeuroscience of Addiction: Relevance to Prevention and Treatment
Volkow, N. D., & Boyle, M. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17101174 · Cited by 322
Self-citationThe histamine H3 receptor: from discovery to clinical trials with pitolisant
Schwartz, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01286.x · Cited by 318
Revealing the structure of pharmacobehavioral space through motion sequencing
Wiltschko, A. B., Tsukahara, T., Zeine, A., Anyoha, R., Gillis, W. F., Markowitz, J. E., Peterson, R. E., Katon, J., Johnson, M. J., & Datta, S. R. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-00706-3 · Cited by 298
Kornum, B. R., Knudsen, S., Ollila, H. M., Pizza, F., Jennum, P. J., Dauvilliers, Y., & Overeem, S. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.100 · Cited by 285
Sleep Neurobiology from a Clinical Perspective
(2011) · Sleep · doi:10.5665/sleep.1112 · Cited by 277
Morbelli, S., Esposito, G., Arbizu, J., Barthel, H., Boellaard, R., Bohnen, N. I., Brooks, D. J., Darcourt, J., Dickson, J. C., Douglas, D., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04817-8 · Cited by 273
Psychostimulants and Cognition: A Continuum of Behavioral and Cognitive Activation
Wood, S., Sage, J. R., Shuman, T., & Anagnostaras, S. G. (2014) · Pharmacological Reviews · doi:10.1124/pr.112.007054 · Cited by 259
Swanson, J., Baler, R. D., & Volkow, N. D. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.160 · Cited by 252
Self-citationThe treatment of cocaine use disorder
Kampman, K. M. (2019) · Science Advances · doi:10.1126/sciadv.aax1532 · Cited by 250
Pharmacological approaches to methamphetamine dependence: a focused review
Karila, L., Weinstein, A., Aubin, H., Benyamina, A., Reynaud, M., & Batki, S. L. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03639.x · Cited by 242
Sleep and circadian functioning: critical mechanisms in the mood disorders?
Harvey, A. G. (2011) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032210-104550 · Cited by 237
“We offer a word of warning related to findings published in the Journal of the American Medical Association that indicate that the potential mechanisms underpinning Modafinil’s alertness-promoting effects involve dopaminergic pathways (Volkow et al. 2009).”
BackgroundThe neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety
Heal, D. J., Cheetham, S. C., & Smith, S. L. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.08.020 · Cited by 198
A double-blind, placebo-controlled trial of modafinil for cocaine dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Plebani, J. G., Pettinati, H. M., Sparkman, T., & O'Brien, C. P. (2012) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2011.12.014 · Cited by 187
Caffeine Increases Striatal Dopamine D2/D3 Receptor Availability in the Human Brain
Volkow, N. D., Wang, G.-J., Logan, J., Alexoff, D., Fowler, J. S., Thanos, P. K., Wong, C., Casado, V, Ferre, S., & Tomasi, D. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.46 · Cited by 163
Self-citationGehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., & Wefel, J. S. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0723-1 · Cited by 161
“However, recent findings have provided evidence for the role of dopamine and norepinephrine in MOD’s pharmacological actions [9, 13, 14].”
BackgroundTardelli, V. S., Bisaga, A., Arcadepani, F. B., Gerra, G., Levin, F. R., & Fidalgo, T. M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05563-3 · Cited by 151
The unknowns of cognitive enhancement
Farah, M. J. (2015) · Science · doi:10.1126/science.aad5893 · Cited by 115
Psychostimulant drugs for cocaine dependence
Castells, X., Cunill, R., Pérez-Mañá, C., Vidal, X., & Capellà, D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007380.pub4 · Cited by 110
Heinzerling, K. G., Swanson, A.-N., Kim, S., Cederblom, L., Moe, A., Ling, W., & Shoptaw, S. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.023 · Cited by 105
Modulatory Effects of Modafinil on Neural Circuits Regulating Emotion and Cognition
Rasetti, R., Mattay, V. S., Stankevich, B., Skjei, K., Blasi, G., Sambataro, F., Arrillaga-Romany, I. C., Goldberg, T. E., Callicott, J. H., Apud, J. A., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.83 · Cited by 83
Acute effects of modafinil on brain resting state networks in young healthy subjects
Esposito, R., Cilli, F., Pieramico, V., Ferretti, A., Macchia, A., Tommasi, M., Saggino, A., Ciavardelli, D., Manna, A., Navarra, R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069224 · Cited by 66
Rowley, H. L., Kulkarni, R. S., Gosden, J., Brammer, R. J., Hackett, D., & Heal, D. J. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113513850 · Cited by 65
“, 2006; Minzenberg and Carter, 2008), positron emission tomography experiments in humans have paradoxically revealed that therapeutic doses of modafinil occupy a substantial proportion of striatal DAT sites in human subjects and increase synaptic dopamine concentrations (Volkow et al., 2009).”
BackgroundGenotype and ancestry modulate brain's DAT availability in healthy humans
Shumay, E., Chen, J., Fowler, J. S., & Volkow, N. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022754 · Cited by 58
Self-citationSleep Deprivation and Cognitive Performance
Killgore, W. D. S., & Weber, M. (2014) · Sleep Deprivation and Disease · doi:10.1007/978-1-4614-9087-6_16 · Cited by 51
Arnold, V. K., Feifel, D., Earl, C. Q., Yang, R., & Adler, L. A. (2014) · Journal of Attention Disorders · doi:10.1177/1087054712441969 · Cited by 48
Addiction theory matters—Why there is no dependence on caffeine or antidepressant medication
Heinz, A., Daedelow, L. S., Wackerhagen, C., & Di Chiara, G. (2020) · Addiction Biology · doi:10.1111/adb.12735 · Cited by 45
Hester, R., Lee, N., Pennay, A., Nielsen, S., & Ferris, J. (2010) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0021791 · Cited by 42
Advances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction
Cao, D.-N., Shi, J.-J., Hao, W., Wu, N., & Li, J. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.03.040 · Cited by 34
Nunez, N. A., Singh, B., Romo‐Nava, F., Joseph, B., Veldic, M., Cuellar‐Barboza, A., Cabello Arreola, A., Vande Voort, J. L., Croarkin, P., Moore, K. M., et al. (2020) · Bipolar Disorders · doi:10.1111/bdi.12859 · Cited by 31
Cope, Z. A., Minassian, A., Kreitner, D., MacQueen, D. A., Milienne-Petiot, M., Geyer, M. A., Perry, W., & Young, J. W. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.07.031 · Cited by 27
“Moda fi nil, a low potency inhibitor of the DAT and norepinephrine transporter (NET), is a Federal Drug Administration-approved compound that was developed to increase wakefulness in the treatment of narcolepsy (Madras et al., 2006; Volkow et al., 2009).”
Karila, L., Leroy, C., Dubol, M., Trichard, C., Mabondo, A., Marill, C., Dubois, A., Bordas, N., Martinot, J.-L., Reynaud, M., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.28 · Cited by 27
Modafinil enhances alerting-related brain activity in attention networks
Ikeda, Y., Funayama, T., Tateno, A., Fukayama, H., Okubo, Y., & Suzuki, H. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4614-9 · Cited by 19
Metadata
- Authors
- Volkow, N. D., Fowler, J. S., Logan, J., Alexoff, D., Zhu, W., Telang, F., Wang, G.-J., Jayne, M., Hooker, J. M., Wong, C., Hubbard, B., Carter, P., Warner, D., King, P., Shea, C., Xu, Y., Muench, L., & Apelskog-Torres, K.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-03-18
- Volume
- 301
- Issue
- 11
- Pages
- 1148
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2055500305
- Cited by
- 529
- References
- 38
- FWCI
- 20.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.